ArticleBMC medical imaging2026
A combi-elasto ultrasound based deep learning model on liver fibrosis staging for suspected MASLD/MASH patients.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMetabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) weakened the diagnostic ability of traditional elastography ultrasound on liver fibrosis. Combi-elasto ultrasound can simultaneously reflect the information of fibrosis degree and fat accumulation, thus have better potential and generality for liver fibrosis. We aim to develop a combi-elasto ultrasound based deep learning (DL) model for fibrosis staging in suspected MASLD/MASH patients.
methodsPatients with overweight, type-2 diabetes, hypertension or dyslipidemia, and without alcoholic, drug-induced, and genetic hepatitis history were defined as suspected MASLD/MASH patients. Fibrosis stages were classified as none or mild (F0/F1), moderate (F2), and severe (F3/F4). Combi-elasto images from ten centers were collected to build the DL model. OpenCV was applied to automatically extract image information, Resnet-50 was used to analyze image feature, and adversarial training (AT) algorithm was introduced to enhance model generality. Traditional DL model without AT algorithm, and other seven classical fibrosis models were also built to compare with AT-DL model. Subgroup analysis on pathological confirmed normal, MASLD and MASH patients were performed to test model generality.
resultsFrom January 2022 to December 2023, 295 patients from eight centers were divided into training (n = 204) and validation (n = 91) sets. 101 patients from two independent centers were collected as external test set. In test set, AT-DL model achieved significantly higher accuracy than traditional DL model (0.871 vs. 0.812, p = 0.021) and all other classical models (0.545-0.762, all p < 0.05). For pathological confirmed normal patients, AT-DL and traditional DL models had comparable accuracy (0.881 vs. 0.905, p = 0.274). However, for pathological confirmed MASLD and MASH patients, AT-DL model showed significantly accuracy than traditional DL model (0.900 vs. 0.800, p = 0.028 and 0.828 vs. 0.690, p = 0.003).
conclusionCombi-elasto ultrasound based AT-DL model had satisfactory performance on fibrosis staging in suspected MASLD/MASH patients, and could reliable non-invasive monitoring of fibrosis progression.
Indexed as
Identifiers
42471585What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.